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Summary 
Cancer is a leading cause of death worldwide. Despite several treatment options such as radiotherapy, 
surgery, chemotherapy and molecularly targeted therapy, and combinations of those, the fight against 
cancer is not satisfying yet. There is no “miraculous cure” and there will never be, since “cancer” is 
only a broad designation of a malady that covers a huge amount of different forms and behaviors. The 
only thing in common is the degenerated control of cells that start to grow uncontrollable, achieved 
through many different mechanisms. Given that, the work on the improvement of existing methods to 
counteract cancer, and on finding and developing new strategies, is of great importance. 
Radiotherapy is one of the most commonly used treatment modalities, alone or in combination with 
another. It induces a complex network of secreted factors that can stimulate tumor outgrowth, 
dissemination, incomplete tumor regression and immune reactions. Irradiation can contribute to tumor 
eradication by damaging cells, respectively their DNA, in an amount that cannot be repaired anymore 
and will lead to mitotic catastrophe that either ends in senescence or death of the cell. DNA damage by 
irradiation is achieved through the formation of reactive oxygen species (ROS), generated through 
radiolysis. ROS are highly reactive and will lead to damage of the DNA and other macromolecules.  
The response and treatment outcome of irradiation is dependent on several factors, described as the 5 
Rs of radiotherapy. These include the repair capacity of the cells and their intrinsic radiosensitivity, 
depending on their position within the cell cycle. After irradiation, the cells will redistribute within the 
cell cycle and repopulate in order to fill up a void created by irradiation-induced cell death. The fifth R 
addresses the reoxygenation between two dose fractions. Reoxygenation is crucial because oxygen 
plays a key role in radiotherapy. It is necessary for the stabilization (“fixation”) of damage induced by 
ROS. Without sufficient oxygen, the survival fraction of irradiated cells is 2.5 to 3 times higher as 
compared to normal oxygenated cells. For this reason, the oxygen status of the tumor is a major 
predictor and influencer of radiotherapy treatment outcome. There are several strategies available to 
increase the amount of oxygen in the blood, and therefore its delivery to a tumor, but they are still not 
fully gratifying.  
In this Master’s Thesis, a novel compound, Myo-Inositoltrispyrophosphate (ITPP), was investigated. It 
was developed as an effector of hemoglobin to lower the affinity of hemoglobin to oxygen. Thereby an 
enhanced release of oxygen e.g. in hypoxic tumors can be achieved. So far, the mode of action remains 
unclear. Further, ITPP has structural similarities to PIP2 and PIP3, which are second messengers 
upstream of the Phosphoinositide 3-kinase / Protein kinase B (PI3K/AKT) pathway, which can 
influence tumor growth and progression.  
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This Master’s Thesis demonstrates that ITPP can modulate the availability of oxygen within a tumor 
and reoxygenate hypoxic tissue. Through the increase of oxygen, the radiosensitivity increases, leading 
to a significant growth delay in vivo, when radiotherapy is combined with ITPP. This was demonstrated 
in an efficacy-oriented experiment of A549 xenografts and in FaDu xenografts. As part of a broad 
mechanistic investigation, histological analysis of tumor oxygenation and of DNA double strand breaks 
(DSB) by γH2AX staining was performed. A significant increase in DNA DSBs in initially hypoxic 
tumor zones could be achieved with ITPP in combination with radiotherapy. Through irreparable 
damage like DNA DSBs, cells will experience radiation-induced loss of clonogenicity, primarily via 
mitotic catastrophe or other modes of cell death.  
These results suggest that a tumor growth delay achieved through a combined treatment modality of 
ITPP and irradiation underlies the induction and “fixation” of DNA DSBs, not only in normoxic but 
also in reoxygenated tumor zones due to ITPPs oxygen-modulatory effect.  
Furthermore, ITPP has also an impact on the PI3K/AKT pathway in vitro, as it upregulates PTEN levels 
and decreases pAKT concomitantly. 
In summary, this Master’s Thesis presents mechanistic investigations on the treatment modality of ITPP 
in combination with radiotherapy in vivo through the oxygen-modulating capabilities of ITPP: more 
ROS can be produced through irradiation, leading to the oxygen-enhancing effect within hypoxic areas 
of the tumor and more extended induction of DNA-double strand breaks. Therefore, ITPP is claimed as 
a potent radiosensitizer and neoadjuvant treatment option for hypoxic tumors.  
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Zusammenfassung 
Krebs ist eine der häufigsten Todesursachen weltweit. Trotz verschiedenen Behandlungsmöglichkeiten 
wie Radiotherapie, Chemotherapie, «molecularly targeted» Therapie oder die chirurgische Entfernung 
von Krebsgewebe, sowie Kombinationen derjenigen, ist die Behandlung von Krebs noch nicht 
zufriedenstellend. Eine Art «Wundermittel» wurde bislang nicht gefunden und wird es auch nicht 
geben, da Krebs nur ein Überbegriff für ein breites Spektrum von deregulierten Zellformen 
und -verhalten ist. Die einzige Gemeinsamkeit stellt das unkontrollierbare Wachstum und die stetige 
Veränderung der vielen Krebsformen dar. Deshalb ist es von grosser Wichtigkeit, die bestehenden 
Behandlungsmöglichkeiten zu verbessern und stetig neue Strategien zu finden und zu entwickeln.  
Radiotherapie ist eine der häufigsten Behandlungsmodalitäten, alleine oder als Kombination. Durch 
Bestrahlung werden verschiedene Antworten provoziert, die von komplexen Signalnetzwerken über 
Immunreaktionen bis zur Umprogrammierung der Krebszellen geht. Zur Vernichtung von Krebszellen 
trägt Bestrahlung durch die Bildung von reaktiven Sauerstoff-Spezies (ROS) bei, welche hoch reaktiv 
sind und DNA und andere Makromoleküle schädigen können. Wenn DNA Doppelstrangbrüche (DSB) 
nicht repariert werden, kann sich eine Zelle nicht korrekt teilen und es kommt zur mitotischen 
Katastrophe.  
Die Reaktion des Krebsgewebes und der Behandlungserfolg der Bestrahlung hängt von verschiedenen 
Faktoren ab, die man gemeinhin als die 5 Rs der Radiotherapie bezeichnet. Dazu gehört die 
Reparaturkapazität der Zellen, DNA DSB effizient zu reparieren (repair). Des Weiteren spielt die 
Position im Zellzyklus eine wichtige Rolle – je nach dem in welcher Phase sich eine Zelle befindet, ist 
sie mehr oder weniger bestrahlungssensitiv (radiosensitivity). Ausserdem kommt es zu einer 
Umverteilung der Zellen innerhalb des Zellzyklus (redistribution) nach einer Bestrahlung, da einige 
Zellen in ihrem Zyklus weiterfahren können, wohingegen andere blockiert sind (durch DNA Schäden). 
Nach einer Bestrahlungsdosis werden einige Zellen irreparable Schäden aufweisen. Es wird ein 
Programm gestartet, welches die Entstehung von Zellklonen mit unvollständigen oder falsch 
organisierten Chromosomensätzen verhindern soll. Das Programm führt entweder zum Tod oder zur 
Seneszenz der Zelle. Die verbleibenden Krebszellen werden versuchen, die entstandene Lücke 
aufzufüllen (repopulation). Das letzte R adressiert die Reoxygenierung zwischen zwei 
Bestrahlungsfraktionen (reoxygenation). Reoxygenierung ist ein wichtiges Thema, da der 
Behandlungserfolg weitgehend vom verfügbaren Sauerstoff im Tumor abhängt. In einem schlecht 
oxygenierten Tumor ist die Reaktion, beziehungsweise die Summe der induzierten und stabilisierten 
DNA DSB, 2.5 bis 3 Mal geringer im Vergleich zu einem normal oxygenierten Tumor. Durch 
Bestrahlung kommt es zur Radiolyse und zur Bildung von ROS. Für die Stabilisierung des ROS-
induzierten Zellschadens ist Sauerstoff essentiell und zählt zu einem der wichtigsten Indikatoren und 
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Faktoren des Behandlungserfolges. Es gibt schon verschiedene Lösungsansätze für hypoxische 
Tumoren um den Sauerstoffgehalt zu erhöhen, doch noch keine, welche vollumfassend wirkt.  
Myo-Inositoltrispyrophosphate (ITPP) ist ein vielversprechendes Molekül, welches die 
Sauerstoffaffinität von Hemoglobin manipulieren kann. Des Weiteren hat es Ähnlichkeit zu den beiden 
sekundären Botenstoffen PIP2 und PIP3, welche oberhalb des Phosphatidylinositol-3-Kinase / Protein 
Kinase B (PI3K/AKT)-Signalweges zu finden sind. Der PI3K/AKT Signalweg kann die 
Tumorprogression und das -wachstum fördern.  
Diese Masterarbeit zeigt, dass ITPP durch seine Hemoglobin-modulierenden Eigenschaften den 
Sauerstoffgehalt in Bereichen mit geringem partiellen Sauerstoffdruck erhöhen kann. Da der Sauerstoff 
den Behandlungserfolg durch Bestrahlung massgeblich erhöht, kann ITPP als Radiosensitizer in vivo 
eingeordnet werden. Dies zeigt sich in einer signifikanten Tumor-Wachstumsverzögerung. In einer breit 
angelegten mechanistischen Untersuchung wurde eine Tumor-Histologie für den DNA DSB Marker 
γH2AX durchgeführt. Durch ITPP in Kombination mit Bestrahlung konnten signifikant mehr DNA 
DSB in initial hypoxischen Regionen der Tumorspezies gezählt werden, verglichen mit einer 
Kontrollbestrahlung. So konnte gezeigt werden, dass der Effekt von Bestrahlung plus ITPP der 
Induktion und Stabilisierung von DNA DSBs in hypoxischen Zonen zugrunde liegt, die sonst 
bestrahlungsinsensitiv sind.  
Ausserdem zeigt ITPP auch einen Effekt auf den PI3K/AKT Signalweg in vitro, da es durch ITPP zu 
einem erhöhten Level von PTEN kommt und zu einer Verminderung von pAKT. 
Zusammengefasst präsentiert diese Masterarbeit mechanistische Hinweise für die Verzögerung des 
Tumorwachstums durch ITPP in Kombination mit Bestrahlung in vivo durch den Sauerstoff-
modulierenden Effekt von ITPP: ROS werden durch Bestrahlung gebildet und schädigen die DNA. 
DNA Schäden wie DSB können durch den nun vorhandenen Sauerstoff fixiert werden. Nicht reparierte 
DNA DSB führen zur mitotischen Katastrophe der entsprechenden Krebszellen. Deshalb kann man 
ITPP als Radiosensitizer einordnen und zur Kombination mit Bestrahlungstherapie für hypoxische 
Tumoren empfehlen. 
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Graphical Abstract 
Figure 1 Overview of the dual function of ITPP. ITPP modulates the affinity of hemoglobin to oxygen and 
interferes with the PI3K/AKT pathway. Thereby, ITPP might reoxygenate hypoxic tissues, which can be 
exploited for radiotherapy. Figures adapted from [40,42,47]. 
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PI3K   Phosphatidylinositol-3-kinases 
PIP2   Phosphatidylinositol-4,5-bisphosphate 
PIP3   Phosphatidylinositol (3,4,5)-trisphosphate 
PKB   Protein kinase B 
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ROS   Reactive oxygen species 
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VEGF   Vascular endothelial growth factor 
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1 Introduction 
1.1 Characteristics of cancer 
Cancer is a broad designation for an extended group of different malignancies. It includes all types of 
neoplastic growth, starting from a benign, but abnormal cell accumulation, resulting in the highly deadly 
and aggressive invasions or spread of cancer cells to other parts of the body. Cancer has not a single 
cause, it is a progressive multistep disorder that transforms normal cells into cancer cells. Several 
mutations in genes controlling cell proliferation and homeostasis must be acquired to transform a 
normal and healthy cell into a malignant, potentially deadly cell. Features that allow cells to become 
cancer cells include traits that enable them to survive, proliferate and disseminate. These different 
characteristics were first summarized by Robert Weinberg and Douglas Hanahan in 2000: "The 
Hallmarks of Cancer" concentrate the complexity of cancer into six main characteristics, that are 
required to become a malignant, invasive cancer cell. The key traits contain sustained proliferative 
signaling, insensitivity to growth suppression, evasion of cell death signaling, limitless replicative 
potential, activation of angiogenesis, invasion into surrounding tissues, and the formation of distal 
metastases. In contrast, normal and healthy cells ensure an appropriate cell number, proper tissue 
architecture and function by strictly controlling their growth and behavior.  
The most characteristic trait of cancerous cells is their uncontrollable proliferation. They evade or 
escape growth suppression, or even apoptotic signaling and moreover, they produce growth factors 
themselves, resulting in a vicious circle of unstoppable growth. In healthy cells, several tumor 
suppressors are active to control proliferation or start a cell death program to avoid extended amounts 
of cells, or as a solution for cells with irreparable damage. Apoptosis serves as a natural barrier to 
develop cancer as it eradicates potential dangerous cells. Through sustaining the proliferative signaling 
and evading cell death, cancer cells have an unlimited proliferative capacity. In addition, replicative 
senescence often can be bypassed. For this fast-replicative behavior, cancer cells need to modify their 
energy metabolism towards glycolysis, and because of their large demand of nutrients, they must induce 
angiogenesis in the surrounding vasculature so that new blood supply can feed the needs of the tumor. 
After a primary excessive growth of cells building a so-called neoplasm, local invasion into the host 
tissue follows. Afterwards, an eventual invasion of tumor cells into the blood stream and dispersion all 
over the body occurs in a process called metastatic cascade. Another key trait of cancer is to evade the 
recognition of the immune system. Some cancer types are even infiltrated with immune cells that can 
cause a local inflammatory response, resulting in more growth and survival factors and enzymes 
   
 
2 
 
facilitating angiogenesis by modifying the surrounding extracellular matrix. Those additional traits 
were added to the initial six hallmarks, resulting in ten hallmarks of cancer [1, 2]. 
1.2 Cancer Treatment Strategies 
With increasing knowledge about mechanisms and characteristics of cancer, treatment has changed 
from relatively general cytotoxic agents to selective and mechanism-oriented therapeutics. The choice 
of the treatment used is based on different characteristics of the cancer addressed: the stage, location 
within the body, grade, genetic makeup, metastatic status and the general health status of the patient.  
In general, cancer can be treated by surgery, radiotherapy, chemotherapy, molecularly targeted therapy 
and combinations of those. If the cancer is in an early stage and locally limited to one location, surgery 
is commonly and successfully used.  
To eliminate potential danger of residing cells, radio- or chemotherapy can be used as part of a 
multimodality therapy. For insights into the stage of a tumor, surgical biopsies are necessary. This is 
important for prognosis and the decision for an appropriate treatment strategy. In severe cases, palliative 
care can be the last reasonable option.  
1.2.1 Radiotherapy 
Radiotherapy (also called X-ray therapy or irradiation) includes the usage of ionizing radiation 
composed of particles, that carry enough energy to liberate electrons from atoms or molecules. It can 
be administered by an external beam or internally via brachytherapy. Usually, external radiotherapy 
with ionizing radiation is generated and delivered by a linear accelerator.  
Figure 2 A graphical summary of the hallmarks of cancer. Figure adapted from [1]. 
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The “absorbed dose” characterizes the amount of energy delivered to matter (especially living tissues) 
by irradiation and reflects the amount of energy deposited per mass. The International System of Units 
describes the absorbed dose as the “Gray” (Gy), which is equal to 1 joule/1 kilogram of matter. 1 Gy 
represents the amount of irradiation required to deposit 1 joule of energy in 1 kilogram [3].  
Through irradiation, DNA can be damaged, leading to radiation-induced loss of clonogenicity. Since 
cancer cells are highly proliferative, they often are in a phase of the cell cycle where they are especially 
prone to DNA damage, in contrast to healthy cells, which are generally less proliferative. Through 
radiolysis, ROS are being produced, leading to several interferences in signaling pathways, repair 
processes and destruction of macromolecules like DNA (Figure 3) [4]. 
Radiotherapy can be curative in several different cancer types, if the tumor is localized in one area of 
the body. It can also be part of adjuvant therapy to prevent tumor recurrence after surgery to remove a 
primary malignant tumor (for example an early stage breast cancer). Further, irradiation acts 
synergistically with chemotherapy and can be used before, during and after chemotherapy in susceptible 
cancers. The susceptibility to irradiation is mostly determined by five factors, commonly known as the 
5 Rs of radiotherapy [3, 5]. 
Figure 3 Irradiation induces the ionization and destabilization of water, leading to the formation of reactive 
radical species. A) These species react with neighboring molecules, forming ROS. B) The hydroxyl radical 
(OH•) is the most cytotoxic among the formed ROS. When generated in the proximity of DNA, they can 
attack DNA. C) This results in the formation of a DNA radical, which is easily reversible. But in the presence 
of oxygen, the DNA damage can be stabilized through oxidation of the DNA radicals. This leads to the 
formation of DNA peroxides. D) The oxygen dependent “fixation” of the DNA damage is known as the 
“oxygen enhancing effect”. Figure adapted from [4]. 
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The 5 Rs of radiotherapy  
The success to kill or minimize cancer cells by localized radiotherapy depends on several factors and 
the interactions of them. Initially, 4 Rs were described by Withers, which include the repair of sublethal 
DNA damage, cell repopulation, redistribution of cells within the cell cycle and the reoxygenation of 
hypoxic tumor areas [6]. An additional fifth R, intrinsic radiosensitivity, was later enclosed by Steel 
[7]. The optimization of these key biological parameters improves the local tumor control and 
minimizes the normal tissue toxicity. Repair or recovery involves the efficient repair of lesions such 
as DNA DSBs. Most of the radiation-induced DNA damage is sublethal and therefore it is effectively 
repaired in normal cells. However, cancer cells have abrogated DNA repair mechanisms. DNA DSBs 
that remain unrepaired can lead to mitotic catastrophe and other modes of cell death. The radiation 
sensitivity varies among the different phases of the cell cycle. In general, cells are most radiosensitive 
in M and late G2 phase and more resistant in late S phase. This pattern of radiosensitivity correlates 
with the mechanism of DNA DSBs repair. The DNA damage in the late S phase is repaired by 
homologous recombination (HR). HR is not as error prone as repair by non-homologous end joining 
(NHEJ), occurring in the early part of the cell cycle. As cancer cells are fast dividing, they are 
heterogeneously distributed in the cell cycle phases. By applying the first dose of irradiation, the most 
sensitive cells will experience mitotic catastrophe or another mode of cell death. The remaining cells 
eventually progress into the next cell cycle phase, which can be more radiosensitive compared to the 
previous one. This is called redistribution. Therefore, fractionation of a dose into two or more fractions 
is used to successfully eradicate most of the cancer cell population. The damage caused by irradiation 
can induce accelerated repopulation as the cells try to fill up the void created by the cells undergoing 
cell death. Because of this reason, repopulation is a common reason for the failure of conventional 
hypo-fractionated courses of radiotherapy. Reoxygenation of the cancerous tissue between two dose 
fractions improves the efficacy of radiotherapy and enhances tumor radiosensitivity. Additionally, 
tumor regions of acute or chronic hypoxia are associated with poor prognosis and aggressive tumor 
progression [3, 6-8]. 
1.2.2 Chemotherapy 
Chemotherapy includes compounds that interfere with the cell’s ability to replicate or to divide the 
chromosomes properly during mitosis. Compounds include alkylating agents, which are highly 
reactive and form bridges between DNA strands. Because of that, the replication machinery cannot 
proceed. Antimetabolites are compounds that can impede DNA or RNA synthesis by competing for 
the active site of an essential enzyme, or molecules that belong to any protein synthesis pathway. 
Topoisomerase inhibitors counteract with the function of the topoisomerase enzyme, which is 
essential for detangling DNA strands during replication. Another class of chemotherapeutic agents 
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presents microtubule-interfering agents, which either prevent the formation of microtubules, or their 
degradation. This has an impact on spindle formation during mitosis, in which doubled chromosomes 
are brought apart for cell division [9]. 
Of course, chemotherapeutic agents are not specific to cancer cells, leading to treatment-induced- 
toxicity in certain tissues, that have a high proliferation rate like skin and hair cells or cells of the 
intestinal linings. Chemotherapy is usually a combination of more than one cytotoxic agents and is 
generally also coupled with another treatment strategy.  
1.2.3 Surgery 
In general, tumors start to grow locally and then spread from the site of formation. In theory, non-
hematological cancers can be cured if they are entirely removed by excision. The goal of surgery can 
be to remove the tumor alone or the whole organ affected. Examples of surgical procedures for cancer 
include mastectomy for breast cancer, prostatectomy for prostate cancer and lung cancer surgery for 
non-small cell lung cancer. Unfortunately, even a small tumor can already spread to other sites within 
the organism and form metastases. Also, a single cancer cell can regrow to another tumor, called 
recurrence. For this reason, a pathologist will examine each excised specimen to determine if a margin 
of healthy tissue is present and thus decreases the chance, that microscopic cancer cells are left in the 
patient. In addition to removal of the primary tumor, it is also necessary for staging. Surgery is often 
performed in combination with other treatments such as chemotherapy or radiotherapy. So far it is not 
clear if surgery before or after another adjuvant treatment has an impact on the survival rate [10, 11]. 
1.2.4 Molecularly targeted therapy  
This class of treatment modality includes several compounds that block the growth of cancer cells by 
interfering with specific targeted molecules needed for tumorigenesis and tumor progression. The most 
successful targeted therapies include compounds that target a protein or enzyme that carries a mutation 
or other genetic alteration that is specific to a cancer entity and not found in the normal host tissue. The 
target specificity reduces side effects within the normal tissue as compared to chemo- or radiotherapy. 
Chemo- or radiotherapy only focuses on the eradication of fast proliferative cells. Therefore, 
molecularly targeted therapy increases the therapeutic window by only focusing on defined molecular 
abnormalities. The most prominent and well-explored targets are the growth factor receptors and 
downstream non-receptor kinase signaling. Targeting cancer metabolism, inhibitors of apoptosis and 
genetic modulation are also emerging strategies to inhibit cancer growth. One of the most successful 
targeted therapeutics is Gleevec, which is a kinase inhibitor. It has great affinity to the oncofusion 
protein BCR-Abl, which is a strong driver of tumorigenesis in chronic myelogenous leukemia. There 
are also targeted therapies for colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, 
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lymphoma, prostate cancer, melanoma and others. Targeted therapies include monoclonal antibodies 
(mAbs), small molecule inhibitors and peptide mimetics. Monoclonal antibody therapy is a form of 
immunotherapy. The mAbs bind monospecifically to certain cells or proteins and thereby stimulate the 
patient’s immune system to attack those cells. Most of the small molecules are tyrosine-kinase inhibitors 
and interfere with the binding and phosphorylation of the substrate of the respective tyrosine-kinase. 
Unfortunately, these molecularly targeted therapies only have drastic response rates in cancers that have 
a specific gene mutation. Therefore, only a small subset of patients will benefit from a molecularly 
targeted therapy whereas the response rates remain marginal across an unselected patient population 
[12]. 
1.3 Oxygen and its involvement in tumor treatment  
Oxygen levels vary within normal tissue and between tumors. The amount of oxygen dissolved in blood 
is usually referred as partial pressure of oxygen: pO2 [13].The physiological pO2 in normal human 
tissues ranges from 20mmHg in liver and brain, to 70mmHg in kidney [14]. When the tissue oxygen 
level falls below physiological levels, the ability to sustain the normal cellular functions is impaired, 
leading to the emergence of pathologic states. This is often summarized as hypoxia. It is important to 
define hypoxia in relation to the oxygen dependence of biological processes, with the potential to 
influence disease behavior and treatment response [14]. Levels of oxygen of about 1% (= 5- 10mmHg) 
correspond to a hypoxic state, whereas levels above are referred to normoxic [15]. In general, pO2 levels 
below 1% lead to an upregulation of hypoxia-inducible factors (HIFs). HIFs are transcription factors 
that mediate the response to decreases in available oxygen in the cellular environment [16].  
In more than 50% of all cancer patients, but depending on the tumor entity, radiotherapy is applied [17]. 
Since the outcome of this treatment modality mainly depends on oxygen, tumor hypoxia represents a 
major challenge for successful radiotherapy [18].  
The direct biochemical effect of oxygen on fixation of DNA damage (Figure 3), as a factor contributing 
to radiotherapy treatment outcome, is maximal at pO2 levels above 5 mmHg [8]. Zones of pO2 below 
this threshold are highly radio-resistant. Additionally, hypoxic cells are also more resistant to anti-
cancer drugs in general because of several reasons;  
First, hypoxic cells are more distant from blood vessels and are therefore less accessible for drugs. 
Second, the proliferation of cells decreases as a function of distance from blood vessels, an effect that 
is at least partially due to hypoxia. Third, hypoxic condition leads to the selection for cells that have 
lost sensitivity to p53-mediated apoptosis, which might lessen the sensitivity to some anti-cancer drugs. 
Fourth, low oxygen levels induce HIF-1 signaling, leading to upregulation of genes involved in drug 
resistance [8]. 
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HIFs are the main players of the response to hypoxia. Among them is HIF-1α. The alpha subunits of 
HIF are hydroxylated at proline residues by HIF prolyl-hydroxylases. Through the hydroxylation, HIF-
1α is recognized by the VHL E3 ubiquitin ligase, which labels it for the rapid degradation by the 
proteasome. The HIF prolyl-hydroxylase uses oxygen as a co-substrate. The hydroxylation functions 
therefore under normoxic conditions, but is abrogated under conditions with insufficient oxygen 
availability. When stabilized, HIF-1α acts as transcription factor and upregulates several genes to 
promote survival in low-oxygen conditions. The response includes the induction of angiogenesis 
through the expression of vascular endothelial growth factor (VEGF). To achieve the transition from 
aerobic to anaerobic metabolism, expression of the glucose-transporter1 (GLUT1) and expression of 
carbonic anhydrase IX (CA-IX) is increased. HIFs also regulate several other genes that promote 
vasodilation, apoptosis, autophagy, oxygen-sensing-invasiveness and metastasis [19]. Additionally, 
tumor cells repress processes in the cell that require higher amounts of energy, such as DNA repair, 
leading to an even more mutant phenotype [20]. Because of this, hypoxia is referred to select for a more 
malignant and invasive tumor, also by promoting metastasis by angiogenesis [21].  
Consequently, reducing tumor hypoxia that can lead to tumor vessel normalization is a promising 
approach in cancer therapy [22]. 
Nonetheless, hypoxia can be exploited by using it for activation of prodrugs. Basically, hypoxia- 
selective cytotoxicity is mediated through a one-electron reduction of a non-operative prodrug, to a 
radical. The oxygen-dependent back-oxidation restores the original compound, thereby producing 
superoxide. Under hypoxic conditions, the back-oxidation does not take place and the prodrug radical 
accumulates. As it is more cytotoxic than the superoxide produced in normoxic cells, hypoxia-selective 
cell killing is achieved [23].  
Hypoxia can also be exploited by hypoxia-selective gene therapy. The promotor which is responsive to 
HIF-1α is used to express proteins able to reduce these prodrugs [24]. Other approaches to exploit 
hypoxia in cancer therapy includes targeting HIF-1α directly [25]. Even recombinant anaerobic, 
genetically engineered, non-pathogenic bacteria, which only grow in the absence of oxygen, can be 
used [26]. 
In summary, hypoxia can be an aid in cancer therapy, using it as an activator for prodrugs, but 
unfortunately it also presents a main hurdle in general, as the prognosis for radio- and chemotherapy is 
worse in hypoxic tumors overall [8]. 
Hypoxia is a defining hallmark of malignancy. It arises from the high metabolic demands of rapidly 
proliferating cancer cells that rely on a dynamic, unpredictable and ineffective microvasculature. 
Hypoxia is not just a microenvironmental by-product of uncontrolled and poorly supported cellular 
growth. It is rather an active participant in the tumorigenesis and the evolution of a cancer over time.  
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1.4 The clinical significance of hypoxia 
The progress in medical genomics and bioinformatics has led cancer research towards the development 
of targeted treatments, to focus on specific molecular or genomic susceptibilities. However, given the 
molecular complexity present in cancer, it became obvious, that highly specific targeted treatments only 
showed great success in a small subset of patients. Only by targeting the pathophysiological 
peculiarities related to specific signaling pathway can lead to a better utility of molecular treatment 
strategies.[27].  
Hypoxia is one of those pathophysiological peculiarities, a mismatch of oxygen supply and demand. 
There is evidence for declaring hypoxia as one of the key determinants of cancer behavior and treatment 
outcome in patients. Although known, one has largely failed to implement this knowledge into clinical 
practice. There are several reasons for this, including the rather difficult identification of the optimal 
patient subgroups for a hypoxia-targeted treatment, the general intensification of the standard treatment 
over the same time frame and the complex interplay between hypoxia and other molecular determinants 
of treatment outcome [28]. The identification of such subgroups is of great importance, because hypoxia 
only has a major influence on treatment outcome when the patient shows a “hypoxia driver phenotype”. 
These patients comprise the population that is most likely to benefit from hypoxia targeted treatments 
[29].  
The most intensely investigated clinical interest includes strategies to improve oxygen delivery to 
tumors: antiangiogenic treatment to decrease an abnormal vasculature structure, breathing hyperbaric 
oxygen, reduction of the cellular oxygen consumption (e.g. by metformin), sensitization of hypoxic 
cells to radiotherapy with hypoxia-targeting agents (e.g. 2-nitromidazole drugs such as nimorazole) or 
direct eradication of hypoxic cells (e.g. with hypoxia activated prodrugs such as evofosfamide) [30]. A 
summary of those attempts is presented in Figure 4.  
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Hypoxia not only decreases the impact of irradiation, it also drives the expression and activation of 
specific signaling cascades promoting survival pathways and angiogenesis and recruits cancer immune 
cells. [31] 
1.5 Biomarkers for prediction of treatment response 
Biomarkers are a possibility to assess and predict the response of cancer cells to an applied treatment. 
For radiotherapy, the initial sensitivity of cancer cells to irradiation is an important parameter to design 
and execute the irradiation schedule. To investigate the mechanics of tumor growth control upon ITPP 
treatment in combination with radiotherapy, biomarkers were essential to track the response of cancer 
cells [7]. 
1.5.1 γH2AX is a DNA double strand break marker 
The intrinsic radiosensitivity relies on the capacity of the cell to repair DNA damage efficiently. 
Perturbed DNA repair mechanisms result in enhanced radiosensitivity. Among the different damages 
irradiation can induce, residual DNA DSBs present the highest lethal potential [32]. The histone variant 
H2AX gets rapidly phosphorylated upon a DNA DSBs, creating γH2AX (phosphorylated H2AX) at the 
chromatin regions that flank the DSB [33]. The phosphorylation of H2AX is a central event of the 
cellular response to DNA DSBs, because it serves as a docking site for various repair factors [34]. The 
number of γH2AX foci per cell is visualized with specific antibodies. It has been shown to correlate 
Figure 4 Summary of the factors influencing the impact of hypoxia on the clinical 
outcome. Hypoxia, even when present to the same extent in different tumors, 
may not have the same effect on clinical outcome because of a possible 
“hypoxia-driver phenotype”. Figure adapted from [29].  
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with unrepaired DSBs, chromosomal aberrations and cell death [35]. The γH2AX foci form very rapidly 
after irradiation and reach plateau levels after 30 minutes. Thereafter, the number of foci decreases until 
they reach a residual level after 24 hours. After dephosphorylation H2AX, cells can re-enter the cell 
cycle by removing the checkpoint arrest [36]. For the mechanistic investigation, γH2AX- assay was 
used to assess the amount of initial and residual DNA DSBs upon ITPP treatment in combination with 
irradiation. 
1.5.2 Pimonidazole as a hypoxia indicator 
Since the oxygen content within a tumor highly influences the outcome of radiotherapy, the reporting 
of tumor hypoxia is crucial. Pimonidazole allows to histochemically assess hypoxia within different 
tissues and cell types. It is a 2-nitroimidazole that is reductively activated specifically in hypoxic cells 
at pO2 levels below 1.3% (±10 mmHg). Once activated, it forms irreversible adducts with thiol groups 
in proteins, peptides and amino acids [37]. Pimonidazole visualizes therefore poorly oxygenated regions 
of histological sections and furthermore, the amount of pimonidazole that can be detected is 
proportional to the hypoxia within the tissue tested [38]. For these reasons, pimonidazole was used to 
identify hypoxic areas in tumor samples and to assess the differences upon ITPP treatment in 
combination with radiotherapy between poorly and well-oxygenated tumor fields.  
1.6 Compound of interest: Myo-Inositoltrispyrophosphate  
Myo-inositoltrispyrophosphate (ITPP) belongs to the family of myo-inositolphosphates; its basic 
structure consists of a cyclohexane ring: myo-inositol. Six phosphate groups are attached to the ring, 
two phosphates form a pyrophosphate through an ester-bond, resulting in three pyrophosphates.  
ITPP was synthesized with 2,3-Bisphosphoglyceric acid (2,3-BPG) as a template. 2,3-BPG is an 
endogenous hemoglobin effector, that among other factors, controls the affinity of hemoglobin to 
oxygen. It binds the deoxygenated hemoglobin and decreases thereby the affinity to oxygen. 2,3-BPG 
allosterically promotes the release of the remaining oxygen molecules. Thus, it enhances the ability of 
red blood cells to release oxygen to cells that need it most, such as exercising cells [39].  
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Phosphatidylinositol-4,5-bisphosphate (PIP2) and Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), 
two second messenger located at the plasma membrane, also contain myo-inositol as basic structure. 
For PIP2 and PIP3, two, respectively three phosphate groups are attached in addition to two long 
hydrocarbon chains which are essential for the location within the plasma membrane [40]. 
ITPP might interfere with two biological processes:  
A) In an oxygen-dependent way: ITPP enters red blood cells via the band 3 anion transporter protein 
and thereupon reduces the affinity of hemoglobin to oxygen.  
B) In an oxygen-independent way: ITPP is involved in the PI3K/AKT pathway since it presents 
similarities to PIP2 and PIP3. 
The effect of ITPP also has been previously investigated by other groups that demonstrated the ability 
of ITPP to selectively enter red blood cells via the band 3 anion transporter protein [59]. Also, the 
suppression of HIF-1α and eradication of early hepatoma in rats upon ITPP treatment was demonstrated 
[53]. Another group observed a stable tumor vessel normalization and increase of PTEN upon ITPP 
administration on the endothelial cell level [55].  
Figure 5  The structure of 2,3-BPG, ITPP, PIP2 and PIP3. Figures adapted from [40,41]. 
Figure 6 Scheme for reoxygenation upon ITPP treatment. ITPP enters red blood cells via band 3 anion transporter 
and reduces the affinity of hemoglobin to oxygen. Figure adapted from [59]. 
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1.7 PI3K/AKT pathway as a target for radiosensitization 
The PI3K/AKT signaling pathway is one of the most critical pathways in the regulation of cell survival. 
The active serine-threonine protein kinase (AKT), also called protein kinase B (PKB), mediates cell 
proliferation, migration, angiogenesis and survival [41-43]. AKT contains two regulatory 
phosphorylation sites, Th308 in the activation loop within the kinase domain and Ser473 in the C-
terminal regulatory domain [44]. The activation of AKT is mediated through Phosphatidylinositol-3 
kinase (PI3K). Signaling of receptor tyrosine kinases upon binding of growth and survival factors 
activate PI3K in turn. PI3K phosphorylates PIP2, which is located at the membrane. The generated PIP3 
recruits AKT to the plasma membrane, where activation steps through different kinases take place. PIP3 
levels are tightly regulated by the action of the Phosphate and tensin homolog phosphatase (PTEN). 
PTEN can remove a phosphate from PIP3 and is therefore the main antagonist of the PI3K/AKT 
pathway and also one of the most frequently mutated tumor suppressors in cancer [45]. The activation 
of the PI3K/AKT pathway can lead to extensive VEGF secretion, both by HIF-dependent and 
independent mechanisms. Enriched levels of VEGF lead to the formation of abnormal vasculature, 
favoring the state of hypoxia [46]. To increase the radiosensitivity, the control of the PI3K/AKT 
pathway is a promising target. The correct regulation of the PI3K/AKT pathway leads to normalization 
of the vasculature and counteracts anti-apoptotic signaling.  
Because of the similarity of ITPP to PIP2, or PIP3 respectively, and the importance of the PI3K/ATK 
pathway in cancer formation and progression, ITPP’s involvement within this pathway also needed to 
be addressed.  
  
Figure 7 Simplified PI3K/AKT pathway. ITPP could interfere with different players within 
the pathway. Its detailed mode of action remains unrevealed. Figure adapted from [42]. 
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1.8 Aim of the project  
ITPP has previously been validated as an oxygen modulator by Ivo Grgic, PhD student in the Laboratory 
of Radiation Oncology at the University Hospital and tutor of this thesis. He demonstrated a significant 
increase in the oxygen concentration upon ITPP treatment within tumor xenografts derived from the 
lung adenocarcinoma cell line A549 (Supplementary 1A).  
Furthermore - as ITPP presents a possible radiosensitizer through its hypoxia antagonizing role - an 
efficacy-study was recently carried out to determine the treatment impact of ITPP in combination with 
irradiation. In xenografted tumors derived from the FaDu head and neck squamous cell carcinoma cell 
line, which is less prone to form hypoxic tumors, a significant growth delay could be observed upon 
ITPP treatment in combination with irradiation (Figure 10A) [47].  
Not all cancers have the same susceptibility for a certain treatment, which is influenced by several 
factors with hypoxia among them. Here, an additional cancer cell line, representing another subtype of 
cancer, was used to test the reoxygenation capability of ITPP and therefore its radiosensitizing effect.  
This leads to the first part of this thesis:  
A) Can ITPP modulate the oxygen content within tumor xenografts derived from the head 
and neck cancer cell line FaDu, which forms less hypoxic xenografts compared to tumors 
derived from the non-small cell lung cancer cell line A549?  
B) Can ITPP also act as a radiosensitizer in a highly hypoxic tumor like in xenografts derived 
from A549 cell line?  
The second and main part of the thesis is about mechanistic investigations of ITPP in vivo. These 
included investigations of the underlying cytotoxic, DNA-damage-oriented mechanism of irradiation 
when combined with ITPP. 
C) How does ITPP and subsequent reoxygenation quantitatively affect DNA damage?  
To investigate this part, a broad trial with histological staining for γH2AX was carried out to 
quantitatively assess initial and residual DNA DSBs upon irradiation in combination with ITPP, within 
hypoxic and normoxic areas of the same tumor.  
Since ITPP has similarities to PIP2 and PIP3, in vitro investigation of ITPPs impact on the PI3K/AKT 
pathway was investigated as part of a side project.  
D) Which effect does ITPP have on the PI3K/AKT pathway in different (cancer) cell lines?  
In summary, this thesis aimed to investigate the capacity of ITPP to modulate hypoxia in different cell 
lines, and consequently, its radiosensitizing effect. Additionally, the effect on the PI3K/AKT pathway 
was investigated.    
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2 Material and Methods 
2.1 Chemicals, Buffers and Solutions 
Chemicals  
0.5 % Trypsin-EDTA 10x  Gibco by Life Technologies  
2-mercaptoethanol Sigma - Aldrich 
Acrylamide   Sigma  
Anti- Phospo-Akt (Ser473) Rabbit mAb Cell Signaling 
Anti- PTEN (138G6) Rabbit mAb Cell Signaling 
Anti β-Actin, Mouse mAb   Sigma Aldrich 
Anti-PI 3 Kinase p110 alpha, Rabbit polyclonal 
IgG  
Upstate Biotechnology 
APS Ammonium Persulfate  BioRad  
Bis-Acrylamide BioRad 
Blotting-Grade Blocker (Milk Powder)  BioRad  
Bromphenol blue Sigma - Aldrich 
Coomaissie solution 0.25% Coomassie Brilliant Blue, 45% methanol, 
10% acetic acid glacial  
Coomassie Brilliant Blue Sigma 
Crystal violet Merck 
Dimethylsulfoxid (DMSO) Sigma - Aldrich 
DMEM Media  Gibco by Life Technologies  
DNA Ladder 1 kb  New England BioLabs Inc.  
ECLTM Anti-Mouse IgG Horseradish Peroxidase 
linked whole Antibody (from sheep)  
GE Healthcare  
ECLTM Anti-Rabbit IgG Horseradish Peroxidase 
linked F(ab)2 fragment (from donkey)  
GE Healthcare  
ECLTM Western Blotting Detection Agents  AmershamTM, GE Healthcare  
EMEM Media Gibco by Life Technologies 
Endothelial Cell Basal Medium with addition of 
endothelial cell growth supplement (Heparin 
0.004mg/ml, basic fibroblast growth factor 
(1mg/ml) and Hydrocortisone (1ug/ml) 
PromoCell  
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Ethanol (EtOH) Merck 
Fetal Bovine Serum Gibco by Life Technologies 
Formalin Kantonsapotheke Zürich 
Glycerol  Sigma  
Glyzine  Fluka 
Hydrochlorid (HCl) Sigma - Aldrich 
Hygromycin InvivoGen 
Isoflurane AbbVie, Baar 
D-Luciferin Perkin Elmer 
Methanol (MeOH) Morphisto  
Myo- Inositoltrisphosphate (ITPP) Normoxys 
Paclitaxel Sigma 
PageRuler Thermo Scientific 
Paraffin Merck 
PBS pH 7.2  Kantonsapotheke Zürich  
Pen Strep (Penicillin/Streptomycin)  Gibco by Life Technologies  
Pimonidazole HPI, Hydroxiprobe Inc. 
Potassium Chloride (KCl) Fluka Biochemika 
Puromycin Dihydrochloride Sigma 
Polyvinylidene difluoride (PVDF) Transfer 
Membrane Amersham- P Hybond 
GE Healthcare  
RPMI Media Gibco by Life Technologies 
Sodium Chloride (NaCl)   Sigma-Aldrich  
Sodium dodecly sulfate (SDS)  Sigma  
Sodium Hydroxide(NaOH) Honeywell 
Tetramethylethylenamidin (TEMED) BioRad  
Trizma® base  Sigma  
Tween® 20  Sigma  
Table 1 Chemicals 
 
 
  
   
 
16 
 
Buffers and Solutions  
Acrylamide solution 30 %, 100 mL  • Acrylamide 29.2 g  
• Bis-Acrylamide 0.8 g  
• add 100 mL ddH2O, sterile filtration, 
store at 4°C in aluminum foil  
10 % APS  • 100 mg APS in 1 mL H2O  
Lämmli buffer • 50 mM Tris HCl  
• 2% SDS  
• 10% Glycerol 
NFMS • 5% skimmed milk in TBS-T 
SDS-sample buffer, 100 mL  • 125 mM Tris HCl pH 6.8  
• 4 % SDS  
• 20 % Glycerol  
SDS Loading Buffer • 50 mM Tris-HCl pH 6.8  
• 2% SDS  
• 10% glycerol  
• 1% β-mercaptoethanol  
• 0.02 % bromophenol blue  
Running Gel buffer  • 1.5 M Tris, pH 8.8  
• 0.1 % SDS  
Stacking Gel buffer  • 0.5 M Tris, pH 6.8  
• 0.1 % SDS   
Transfer buffer  • 25mM Tris HCl 
• 192mM Glycine 
• 0.1% SDS 
• 20% MeOH 
TBS (10 x)   
  
• NaCl 80 g  
• KCl 2 g  
• Tris 30 g  
• add 1 L ddH2O, pH 7.4  
TBS-T • 1 X TBS + 0.1% Tween20 
Table 2 Buffers and Solutions 
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2.2 In vitro: assessment on the effect of ITPP on different cell lines 
2.2.1 Cell culture 
The human squamous head and neck cancer cell line FaDu was cultured in EMEM cell culture media 
containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S). The human umbilical 
vein endothelial cell line HUVEC was cultured in ECBG cell culture medium supplemented with 
endothelial cell growth media. The non-small cell lung carcinoma cell line A549 was cultured in 
RPMI1640 cell culture medium, supplemented with 10% FBS and 1% P/S. The cells were cultured as 
monolayers in culture plates in a 37°C humidified atmosphere containing 5% CO2 (Binder incubator). 
Cell culture work was conducted once to twice a week. For HUVECs, bio-coated cell ware was used.  
ITPP was provided by NormOxys, dissolved in PBS and further diluted with cell culture media for 
treatment.  
Cell lines 
A549 Human non-small cell lung carcinoma ATCC® CCL-185™ 
FaDu Human head and neck squamous cell carcinoma ATCC® HTB-43™ 
HUVEC Human umbilical vein endothelial cells ATCC® CRL-1730™ 
Table 3 Cell lines 
2.2.2 Irradiation of cells 
Cells were irradiated with 0, 2, 4 and 6 Gy using an Xstrahl 200 kV X-ray unit at 1 Gy/min (Gulmay, 
Suwanee GA). 
2.2.3 Western Blotting 
For sample preparation, media was removed from the petri dishes and cells were washed once with 
PBS. For harvesting, the cells were scraped off in Lämmli Buffer and heated for 5 min at 95°C, shaking 
at 1000 rpm (Thermomixer compact, Eppendorf). The protein concentration was determined by 
Nanodrop 1000 (Spectrophotometer, Thermo Scientific).  
Samples were stored at -20°C.  
Protein samples (50µg) from whole cell lysates were size separated by SDS-PAGE in 10% acrylamide 
gels and transferred to a polyvinylidene difluoride (PVDF) membrane using a semi-dry transfer unit 
(TE70X, Hoefer). A PageRuler prestained protein ladder was used as a marker. 
• Running gel: 10%: 30% acrylamide 5ml, running gel buffer 3.75ml, H2O 6.25ml, TEMED 
10µl, 10% APS 100µl 
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• Stacking gel: 30% acrylamide stock 1.3ml, stacking gel buffer 2.5ml, H2O 6.1ml, TEMED 
10µl, 10% APS 50µl 
After the transfer, membranes were blocked in 5% non-fat milk solution (NFMS) for 1h at room 
temperature before overnight incubation at 4°C with different primary antibodies (1:1000 in 5% 
NFMS). Before and after membranes were probed for primary antibody with anti-rabbit (1:2000) and 
anti-mouse (1:2000) ECL peroxidase conjugates, they were washed three times for at least 15 min with 
TBS-T. The resulting chemiluminescent complexes were identified by ECLTM Western Blotting 
detection agents by a Vilber Lourmat Fusion FX Detector. Images were stored as TIF files for analysis.  
2.2.4 In vitro ITPP treatment  
Per treatment, 200’000 cells were seeded in 2ml medium and allowed to grow and adhere overnight. 
The cells were treated with 10mM ITPP for different time periods (2h, 6h, 24h, 48h) and cultured in 
either hypoxic or normoxic condition. 
• Hypoxic condition: 37°C, 5% CO2, 0.2% O2, in a humidified Scholzen incubator  
• Normoxic condition: 37°C, 5% CO2, 19% O2, in a humidified Binder incubator.  
After treatment, cells were harvested for Western Blot analysis (3.2.3). 
2.2.5 Proliferation assay 
For the proliferation assay, transparent 96-well plates were used. The outer rows were filled with PBS 
to prevent evaporation. For every timepoint (0h, 24h, 48h, 72h) and every condition, triplets were 
performed. The proliferative activity was measured by the capacity of the cells to metabolize 
AlamarBlue (Biosource International, Camarillo, CA). Through metabolization within the cell, 
AlamarBlue is irreversibly reduced to the pink colored and highly red fluorescent resorufin. The change 
in absorbance can be measured and indicates the proliferative activity. Exactly 3h prior measuring the 
absorbance, 10µl AlamarBlue was administered to the corresponding wells. The absorbance at 590nm 
and 630nm was measured by the Tecan GENios spectrophotometer.  
2.2.6 Clonogenic cell survival assay 
To investigate the ability of cells to form colonies, clonogenic cell survival assays were performed. 
Cells were seeded in petri dishes to obtain ± 50 colonies. Cells were preincubated with 10mM ITPP for 
different time periods (2h, 6h and 24h) and irradiated with 0, 2, 4 and 6 Gy using an Xstrahl 200 kV X-
ray unit at 1 Gy/min (Gulmay, Suwanee GA). Cells were allowed to form colonies for at least 15 days. 
For fixation of the colonies, the media was removed, and the cells were washed once with PBS. The 
cells were incubated for 1-2 h with methanol/acetic acid 3:1. After removal of the methanol/acetic acid 
mixture, the plates were left to dry overnight at room temperature (RT). Afterwards, the colonies were 
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stained by overlaying the plates with crystal violet for 30 min. The staining mixture was removed by 
gentle washing with tap water and the plates were left to dry overnight at RT. For the evaluation of the 
assay, the colonies formed were counted manually with a colony counter (Gallenkamp). The plating 
efficiency (PE) was calculated by dividing the number of colonies by the cells seeded on the control 
plate (here 0 Gy). The survival fraction (SF) could be calculated the following way: SF=
Colonies counted
Cells seeded
PE⁄
 
[3].  
2.3 In vivo assessment of ITPP impact 
All in vivo experiments were performed according to the guidelines of welfare and use of animals of 
the Veterinäramt Zurich, Switzerland. 
2.3.1 Animals 
Female athymic CD1 nude mice (Charles River) were kept in appropriate conditions.  
2.3.2 Subcutaneous injection for xenograft generation 
For each xenograft, 4×106 cells (in 250µL PBS) were injected subcutaneously in the flank of athymic 
CD1 nude mice under anesthesia with Isoflurane. Tumor growth was measured and determined from 
Caliper skin measurements of tumor length (L) and width (l) according to the formula 
𝐿 × 𝑙2
2
. Tumors 
were allowed to expand to a volume of 300mm3 (±10%) before treatment start and random assignment 
of animals to the experimental groups. 
2.3.3 ITPP treatment and pimonidazole injection 
3g/kg bodyweight ITPP was injected intraperitoneally (i.p.). ITPP was dissolved in PBS and pH was 
adjusted to physiological pH using 1M NaOH.  
60mg/kg bodyweight pimonidazole was injected i.p. 4h before treatment start. Pimonidazole was 
dissolved in 0.9 % NaCl solution. 
2.3.4 Dynamic in vivo imaging system: IVIS 
IVIS is a Living Image system by Perkin Elmer, enabling to acquire and analyze luminescent or 
fluorescent signals in real-time and it provides tools for optimizing image display and analyzing images 
or kinetic data. The Living Image 3.2 software was used to obtain bioluminescent pictures [48] (Caliper 
Life Sciences). Luminescence signal was measured right before ITPP treatment as a baseline and 
corrected for tumor volume.  
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To observe the capacity of ITPP to be an oxygen- modulator, an in vivo bioluminescence reporter 
system was used.  
In brief, a part of the oxygen dependent degradation (ODD) domain of HIF-1α is fused to luciferase 
and constantly expressed in the cancer cell line of interest. Under normoxia, the ODD domain is 
hydroxylated by HIF prolyl-hydroxylase at two proline residues, leading to the degradation of HIF-1α 
protein by the proteasome. Under hypoxia, the proline is not hydroxylated, leading to stabilization of 
the protein and expression of luciferase. This can be used as a reporter for hypoxia under low oxygen 
concentration. The bioluminescence signal is increased compared to normal oxygen concentrations 
because of the stable expression of luciferase, which can convert the injected luciferin into a measurable 
bioluminescent signal.  
When sufficient oxygen is present, the luciferase is rapidly degraded due to its fusion to the ODD 
domain. Therefore, a strong bioluminescent signal upon luciferin application represents hypoxia, 
whereas a decrease in the luminescent signal refers to an increase in oxygen [49]. 
To test the oxygen-modulating capabilities of ITPP, tumor xenografts derived from FaDu cell line in 
athymic CD1 nude mice were used.  
Treatment started when the tumor reached a volume of 300mm3 ± 10% and animals were randomly 
assigned to an experimental group. Prior to the injection of ITPP (3g/kg bodyweight) or PBS as a 
control, a baseline of the bioluminescence signal was acquired. 2h after the treatment injection, the first 
bioluminescent measurement was taken. ITPP was applied on two consecutive days. The dose- and 
time window for maximal ITPP effect was already identified in a previous project, in another tumor 
model [47]. 
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2.3.5 PXi and SmART for irradiation design and execution 
The precision X-ray X-RAD 225Cx (PXi) machine is a small animal image guided irradiation system. 
It has the feature to acquire optical images in addition to cone beam CT (CBCT) scans. Pilot X-ray 
software 1.14.1 was used to scan the tumors and execute irradiation treatment. To individually design 
a treatment, the planning software SmART-Plan, version 2.0 November 2014, was utilized [50][51]. 
With the PXi, maximal target accuracy for irradiation was ensured. An example for a treatment plan is 
presented in Figure 8. 
2.3.6 γH2AX assay 
A549-derived xenografts were generated as described in 2.3.2. Treatment started at a tumor volume of 
300mm3 ± 10%. 4h before treatment, pimonidazole was injected i.p. at 60mg/kg bodyweight. Treatment 
was applied on two consecutive days and eventual irradiation with 4 Gy took place 2h after the second 
injection. The tumor was stored in formalin immediately after excision and embedded into paraffin 24h 
thereafter. In contrast to the efficacy-oriented experiment with FaDu-derived xenografts (Figure 10A), 
irradiation intensity for the γH2AX assay was chosen to be 4 instead of 5 Gy to avoid induction of too 
many γH2AX foci per cell, ensuring proper counting of single γH2AX foci [34].  
Figure 8 Example of a SmART treatment plan for xenograft irradiation using PXi. CT scans from sagittal, coronal 
and axial view. The irradiation beam is presented in green.  
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Three consecutive 3µm specimen cross-sections from the paraffin-embedded tumor material were 
stained for  
a) hematoxylin and eosin (H&E),  
b) pimonidazole  
c) and γH2AX  
The preparation and staining of tumor sample slides was carried out by SophistoLab, Muttenz and the 
scanning by a digital color camera in the Pathology Department of the University Hospital Zurich. 
For the evaluation, three hypoxic zones (pimonidazole-positive staining) and three normoxic zones, 
were chosen for each tumor sample and γH2AX foci were counted manually in at least 100 cells in the 
defined zones.  
Foci analysis was performed in intact and viable cell nuclei only. Mitotic, necrotic or cells that showed 
micronuclei were excluded from the analysis. This was decided upon H&E staining. Number of foci 
was normalized to nucleus volume using ImageJ.  
2.4 Statistical analysis 
Statistical analysis was performed with GraphPad Prism 7. Data is represented as mean ± SEM. The 
data was analyzed using student t test, Mantel-Cox test or one-way Anova.  
P ≤ 0.05 was considered significant.  
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3 Results 
3.1 In vivo assessment of ITPP as a combined treatment with radiotherapy 
3.1.1 ITPP acts as a hypoxia modulator 
In order to assess tumor reoxygenation in response to ITPP treatment, an in vivo bioimaging approach 
was used, in which the oxygen degradation domain (ODD) of HIF-1α is fused to luciferase and 
expressed in the cell line of interest, in this case FaDu head and neck squamous cell carcinoma cells. 
The effect of ITPP was tested in FaDu-derived xenografts growing in athymic CD1 nude mice, to 
complement the experimental series of Ivo Grgic, who performed the reoxygenation-experiment 
already in A549-derived xenografts and carried out an efficacy-study in FaDu-derived xenografts 
(Figure 10A) [47]. Treatment started at a tumor volume of 300mm3 ±10% and animals were randomly 
assigned to an experimental group. ITPP or PBS was injected on two consecutive days. 2h after each 
injection, the bioluminescence signal was measured and normalized to a baseline bioluminescence 
signal and tumor volume.  
A significant decrease in tumor bioluminescence was detected 2h after the second ITPP treatment 
(Figure 9B), indicating a significant increase of the oxygen concentration within the tumor (p=0.03, 
student t-test), as compared to tumors treated with PBS (Figure 9A). The same effect was previously 
observed in A549-derived xenografts; The decrease in hypoxia was already significant 2h after the first 
ITPP injection (Supplementary 1A) [47].  
Collectively, this result indicates that ITPP can significantly decrease hypoxia in A549- and FaDu-
derived xenografts in athymic CD1 nude mice.  
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Figure 9 Reoxygenation of FaDu-derived xenografts upon ITPP treatment: representative images 
illustrating the effect on ITPP treatment as compared to control treatment on tumor reoxygenation, 
detected by a hypoxia-specific bioluminescent in vivo bioimaging approach. A) For control treatment, 
there is no significant change in luciferase activity detectable within the FaDu-derived xenograft. B) 
2h after the second ITPP treatment, there is a significant decrease in luminescent signal observable, 
indicating an increase in oxygen. 
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3.1.2 ITPP in combination with irradiation leads to a significant growth delay in tumor 
xenografts 
The results obtained with the in vivo bioluminescence imaging system suggest, that ITPP treatment with 
a subsequent increase in tumor oxygenation might sensitize for irradiation [3]. Irradiation acts upon 
formation of ROS that can induce DNA damage. This damage can be further stabilized through 
additional ROS. For the fixation of DNA damage, oxygen is required [4]. In theory, by lowering tumor 
hypoxia, the response to irradiation is more effective in a reoxygenated tumor as compared to a hypoxic 
tumor. Oxygen enhancement ratios for up to 2.5 to 3 were identified [3]. 
To test the effect of ITPP as a “reoxygenator” and therefore its capacity to act as radiosensitizer, A549-
derived xenografts in athymic CD1 nude mice were treated with a single fraction of irradiation alone 
and in combination with ITPP. Treatment started at a tumor volume of 300mm3 ±10% and animals were 
randomly assigned to an experimental group. ITPP or PBS respectively was injected on two consecutive 
days. The xenografts were irradiated with 5 Gy 2h after the second treatment, using an image-guided 
small animal radiotherapy platform (XRAD 225Cx, precision X-ray). The radiotherapy platform is 
linked to the SmART planning software. With this software, a detailed treatment plan could be designed 
and executed. Maximal target accuracy was ensured (2.3.5). The treatment schedule outline was based 
on the previous efficacy-study within FaDu-derived xenografts treated with ITPP in combination with 
irradiation. This experiment was performed by Ivo Grgic (Figure 10A). The experiment was conducted 
in xenografts derived from the head and neck squamous cell carcinoma (HNSCC) cell line FaDu 
because of the interest claimed by NormOxys and the clinical relevance of HNSCC. A significant tumor 
growth delay upon combination treatment of ITPP with irradiation was demonstrated (p=0.03, student 
t-test). The tumor growth delay upon irradiation in combination with ITPP was also significant in A549-
derived xenografts as compared to irradiation treatment alone (p=0.05, student t-test) (Figure 10B). 
Monotreatment of ITPP did not exert in any tumor growth delay as compared to control treatment 
(PBS). 
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Figure 10 Tumor growth delay upon ITPP treatment in combination with irradiation. A) FaDu-derived xenografts 
were irradiated with 10 Gy (experiment performed by Ivo Grgic). B) A549-derived xenografts were irradiated with 
5 Gy. Monotreatment with ITPP did not have any effects on tumor growth of FaDu- and A549-derived xenografts.  
Furthermore, the absolute growth delay to quadruple the initial tumor volume (300 mm3) of A549-
derived xenografts was most enhanced in response to the combined treatment modality when compared 
with the absolute tumor growth delay in response to irradiation alone. Median survival for treatment 
with ITPP in combination with irradiation was 78d and the irradiation only average survival was 42d. 
The survival was significantly prolonged (p=0.02, one-way Anova) for combined treatment modality 
of ITPP and irradiation (Figure 11). 
The results obtained from the efficacy-studies in xenografts derived from A549 and FaDu cell line 
indicate that ITPP in combination with irradiation can lead to a significant tumor growth delay and 
prolonged survival.  
  
Figure 11 The median survival of mice bearing A549-derived xenografts upon combination treatment with ITPP 
and irradiation was significantly prolonged as compared to mice bearing A549-xenografts that received 
radiotherapy only.  
   
 
27 
 
3.1.3 Mechanistic investigation of ITPP in combination with irradiation shows significant 
increase in number of DNA DSBs within initially hypoxic areas 
In order to complement the previously performed efficacy-oriented experiments in FaDu-derived 
xenografts, the effect of ITPP in combination with irradiation was assessed on the level of the DNA 
DSB induction using the DSBs marker γH2AX. To do so, FaDu-derived xenografts were treated with 
PBS, ITPP and irradiation (4 Gy) alone and combined. Treatment (3g/kg bodyweight ITPP/PBS) was 
injected on two consecutive days, and tumors were irradiated 2h after the second treatment injection. 
When the tumor xenograft reached a volume of 300mm3 ± 10%, pimonidazole was injected i.p. at 60 
mg/kg bodyweight in order to mark the hypoxic areas within the tumor. 4h thereafter, treatment with 
ITPP or PBS was initiated with animals randomly assigned to the different experimental groups. 
Tumors were harvested for histological characterization at a short term timepoint (0.5h after irradiation) 
or at a later timepoint (24h after irradiation). Directly after excision, tumors were stored in formalin and 
24h later embedded in paraffin. Preparation of histological slides was carried out by SophistoLab, 
Muttenz. For each sample, three normoxic and three hypoxic zones were identified and in each zone, 
γH2AX foci of at least 100 cells were counted. 
The relative frequency of γH2AX foci per cell in normoxic zones for unirradiated xenografts did not 
vary for either ITPP or control treated animals for any timepoint. 20 – 25% of the cells did not show 
any γH2AX foci at all (Figure 13A).  
Figure 12 Representative tumor-histology slide stained for pimonidazole and γH2AX. γH2AX appears as brown  
foci within the cell nucleus. The squares represent samples within hypoxic zones (pimonidazole-positive: brown, 
left) or normoxic zones (pimonidazole-negative: blue, right), with one representative picture of each treatment (ITPP 
and PBS in combination with irradiation).  
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The hypoxic zones within unirradiated xenografts present a similar number of γH2AX foci per cell as 
cells within normoxic, unirradiated fields. There is no significant difference between ITPP treated and 
PBS treated hypoxic zones in regard to the average number of γH2AX foci per cell (Figure 13B).  
Looking at the short term timepoint (0.5h) after irradiation, there were differences between hypoxic and 
normoxic zones.  
The number of γH2AX foci per cell within the normoxic zones is similar for ITPP monotreatment and 
control treatment. Nevertheless, there are slightly more γH2AX foci per normoxic cell upon ITPP 
treatment combined with irradiation at the short term timepoint (0.5h after irradiation) (Figure 14B).  
Shortly after irradiation, hypoxic cells had in average significantly more γH2AX foci per cell when 
treated with ITPP as compared to control irradiated hypoxic cells (p=0.0006, student t-test) (Figure 
14A). This resulted in a right shift within the distribution curve of average γH2AX foci per cell. Nearly 
0% of hypoxic ITPP treated cells had zero foci whereas 10% of hypoxic control irradiated cells had no 
γH2AX foci (Figure 14A right). 
Also, for the long term timepoint after irradiation (24h), cells that were hypoxic prior ITPP treatment 
had more γH2AX foci per cell in average, as compared to hypoxic cells that were only treated with 
irradiation (p=0.0001, students t-test). 15% of the control irradiated hypoxic cells had zero γH2AX foci 
per cell, whereas for hypoxic cells treated with ITPP and irradiation, only 5% had no γH2AX-foci 
(Figure 14C). 
Interestingly, irradiated normoxic cells also had more γH2AX-foci per cell at the long term timepoint, 
when treated with ITPP as compared to control irradiated cells, but almost 15% of control irradiated 
cells had no γH2AX-foci whereas upon ITPP treatment, only 5% of the cells had no foci (Figure 14D). 
Figure 13 Relative frequency of cells with different numbers of γH2AX foci in unirradiated xenografts within A) 
normoxic cells and B) hypoxic cells. There was no difference in average γH2AX foci per cell for either ITPP nor 
PBS treatment at any timepoint.  
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Overall, these results suggest that in initially hypoxic cells (pimonidazole-positive) treated with ITPP 
in combination with radiotherapy, more γH2AX foci per cell were induced, compared to hypoxic cells 
that only received irradiation treatment. Normoxic cells treated with ITPP and radiotherapy also have 
in average more γH2AX foci per cell, compared to normoxic cells that were only irradiated.  
  
Figure 14 γH2AX foci per cell in irradiated xenografts. A) 0.5h after irradiation initially hypoxic cells (pimonidazole-
positive) had in average more γH2AX foci per cell as compared to hypoxic cells that only received irradiation. 0% of 
ITPP treated and irradiated initially hypoxic cells had zero foci, whereas 10% of control irradiated hypoxic cells had 
no foci. B) 0.5h after irradiation, normoxic cells that were ITPP treated had slightly more γH2AX foci per cell. C) At 
a long term timepoint after irradiation (24h), there were overall less γH2AX foci per initially hypoxic cell. ITPP treated 
and irradiated cells still presented more γH2AX foci per cell in average and less cells with no γH2AX foci. D) For the 
long term timepoint after irradiation, normoxic ITPP treated cells still presented more γH2AX foci per cell as 
compared to control irradiated normoxic cells.  
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3.2 In vitro assessment of ITPP acting on the PI3K/AKT signaling pathway 
Given the importance of the PI3K/AKT pathway in tumorigenesis and progression, the effect of ITPP 
was assessed within this pathway. By Western Blotting, protein levels of the key players within the 
PI3K/AKT pathway were assessed upon ITPP treatment. These experiments were performed as a side 
project and have not been carried out to full extent. Nevertheless, some of the results were included in 
this thesis. 
3.2.1 ITPP-dependent increase of PTEN in normoxia and hypoxia 
To assess the impact of ITPP on the PI3K/AKT pathway, Western Blots of whole cell lysates were 
performed and probed for different proteins within the PI3K/AKT pathway upon ITPP treatment. Cells 
were incubated for different time periods (2h, 6h, 24h and 48h) with 10mM ITPP or PBS. Cells were 
cultured in either normoxic or hypoxic conditions. The Western Blot was probed for PTEN, PI3K, 
pAKT and β-actin. AKT was not probed in this experiment because only the active form (pAKT) was 
of interest.  
For the A549 cell line, an ITPP-dependent increase in PTEN was observed at the 24h time point (Figure 
15A). Although there was also an increase in PTEN observed in PBS treated A549 cells over time 
(maximal after 48h), the decrease in pAKT was only present upon ITPP treatment. Within the FaDu 
cell line, an ITPP-dependent increase in PTEN was observed over time and simultaneously a decrease 
in pAKT level (Figure 15B). 
Within hypoxic condition, the increase in pAKT was abolished upon ITPP treatment in A549 cell line, 
in comparison to A549 cells treated with PBS (Figure 15C). The hypoxia-dependent increase in pAKT 
was also demonstrated in FaDu cell line treated with PBS, but upon ITPP treatment, a decrease in pAKT 
was observed. Concomitantly, a slight increase in PTEN was present in FaDu cell line upon ITPP 
treatment (Figure 15D).  
A similar response to ITPP treatment was demonstrated in HUVECs (data not shown).  
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Figure 15 Representative Western Blots probed for different proteins within the PI3K/AKT pathway derived from 
A549 (left) and FaDu (right) whole cell lysates. The cells were incubated for different time periods with 10mM ITPP 
or PBS in normoxic or hypoxic conditions. A) A decrease in pAKT level was demonstrated in an ITPP-dependent 
manner in normoxic conditions in A549 cell line. B) An ITPP-dependent increase in PTEN was demonstrated in 
FaDu cell line and a concomitant decrease in pAKT level. C) Under hypoxic conditions, the hypoxia-dependent 
increase in pAKT level was abolished upon ITPP treatment in A549 cell line. D) The ITPP-dependent decrease in 
pAKT level under hypoxic conditions was also observed in FaDu cell line.  
3.2.2 ITPP-dependent increase of PTEN upon combination with irradiation 
In order to assess the response in cells treated with ITPP in combination with irradiation, FaDu cells 
and HUVECs were seeded and treated with 10mM ITPP 2h prior to irradiation with 2 Gy. Protein levels 
were assessed at different timepoints after irradiation (0.5h, 4h and 24h) by Western Blotting. The 
Western Blot was probed for PTEN, PI3K, pAKT and β-actin. AKT was not probed in this experiment 
because only the active form (pAKT) was of interest. 
Upon irradiation, an ITPP-dependent increase in PTEN and a simultaneous decrease in pAKT level was 
demonstrated in FaDu cell line (Figure 16A) compared to FaDu cells that only received radiotherapy in 
which PTEN level decreased. In HUVECs treated with ITPP in combination with irradiation, the ITPP-
dependent increase in PTEN was also demonstrated and the concurrent decrease in pAKT was observed 
(Figure 16B).  
A similar response to ITPP in combination with irradiation was demonstrated in A549 (data not shown).  
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Figure 16 Representative Western Blots probed for different proteins within the PI3K/AKT pathway derived from 
A549 and FaDu whole cell lysates. The cells were pre-incubated for 2h with 10mM ITPP or PBS and harvested 
at different timepoints after irradiation with 2 Gy. A) An ITPP-dependent increase in PTEN level was demonstrated 
in FaDu cell line. In combination with irradiation, the increase in PTEN is more intense as compared to ITPP 
treatment only. pAKT levels were demonstrated to decrease concomitantly. B) The ITPP-dependent decrease in 
pAKT levels was also demonstrated in HUVECs. The decrease in pAKT was present in cells with ITPP 
monotreatment and in combination with irradiation. 
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3.2.3 Proliferation and clonogenic cell survival assays of FaDu cells demonstrated no 
difference upon ITPP treatment 
Since the PI3K/AKT pathway has a major effect on proliferation and survival (1.7), ITPP treatment 
might have an impact on the proliferative activity of different cell lines. The proliferative activity of 
FaDu cells was assessed in 96-well plates with the colorimetric AlamarBlue assay (Biosource 
International). In order to investigate the impact of ITPP, the cells were incubated with 10mM ITPP or 
PBS for different time periods (2h, 6h and 24h) and irradiated with increasing doses (0, 5, 10 Gy). In 
comparison to FaDu cells that only received radiotherapy, ITPP treatment did not evoke any difference 
in proliferative activity alone or in combination with irradiation.  
Similar results were obtained for ITPP treatment in combination with irradiation for the proliferative 
activity of A549 cells or HUVECs (data not shown).  
To quantify the effect of ITPP activity on cellular survival and radiosensitivity, clonogenicity was 
determined. The clonogenic cell survival of FaDu cells pre-treated with 10mM ITPP or PBS for 
different time periods (2h, 6h, 24h) and irradiated with increasing dose of irradiation (0, 2, 4 and 6 Gy) 
did not show any difference regarding clonogenicity of the FaDu cells. The formation of colonies was 
allowed for 15 days (data not shown).  
Collectively, these in vitro results demonstrated an ITPP-dependent increase of PTEN in hypoxic and 
normoxic conditions and a concomitant decrease in pAKT. Upon irradiation in combination with ITPP, 
the irradiation-induced increase in pAKT was abolished. Of note is, that ITPP in combination with 
irradiation did not promote any difference in proliferative activity of the tested cell lines (A549, FaDu, 
HUVECs), nor in clonogenicity in FaDu cells.  
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4 Discussion 
The focus of this Master’s Thesis was to address how a specific chemical compound, namely Myo- 
Inositoltrispyrophosphate, renders tumors more radiation-sensitive via modulation of the tumor hypoxia 
status.  
Hypoxia can arise through several factors within a tumor leading to a selection of tumor cells with a 
more aggressive and treatment-resistant phenotype. Owing to hypoxia, not only chemotherapy is not 
properly delivered, even treatment outcome after surgery is worse [13, 15, 30]. The strongest impact of 
hypoxia can be observed when tumors are treated with radiotherapy; 
Ionizing radiation leads to the production of ROS, which can induce DNA DSBs. Because of DNA 
DSBs, cells cannot properly divide and will experience mitotic catastrophe. A program will be initiated 
to prevent the formation of cells with incomplete chromosome numbers, leading to cell death or 
senescence [52]. The fixation of DNA DSBs requires oxygen. In normoxic cells, this fixation is 
possible, but not in hypoxic cancer cells. Therefore, in tissues with pO2 < 5 mmHg (1%), the response 
to irradiation is up 2.5 to 3 times lower as compared to a well oxygenated (cancer) tissue [4, 19, 29]. 
For this reason, addressing tumor hypoxia and its modulation through different strategies is of great 
importance. To rise the pO2 within the tumor, several possibilities are present:  
To increase the delivery of oxygen, antiangiogenic treatment (in order to induce normalization of the 
tumor vasculature), the breathing of hyperbaric oxygen or other gases with high oxygen concentration 
have been preclinically and clinically tested. Another solution can be to reduce cellular oxygen 
consumption (e.g. by metformin) or to selectively eradicate hypoxic cells using hypoxia-activated 
prodrugs (e.g. by evofosfamide) (1.4).  
In this Master’s Thesis, a further approach to decrease hypoxic areas within tumors was explored: the 
use of Myo-Inositoltrispyrophosphate (ITPP). The aims of the thesis included validation of ITPP as an 
oxygen-modulator in an additional tumor model, and assessment of its capability to act as a 
radiosensitizer through its pO2 increasing potential.  
In the main part of this thesis, the mechanism underlying the tumor growth control upon ITPP treatment 
in combination with irradiation was investigated. It was demonstrated that upon ITPP treatment, more 
DNA DSBs could be induced and stabilized (“fixed”) in initially hypoxic cells, compared to hypoxic 
cells within tumors which only received radiotherapy. An additional side project included the in vitro 
investigation on the PI3K/AKT pathway, since ITPP structurally resembles the two molecules PIP2 and 
PIP3 which act upstream of this pathway. The PI3K/AKT pathway is relevant for cancer research, as it 
is one of the major mediators of cell growth and survival, and is often hyperactivated in cancer cells.  
   
 
35 
 
4.1 ITPP as an oxygen-modulator sensitizes hypoxic tumors for radiotherapy 
Previously it was demonstrated, that ITPP treatment can modulate the oxygen-content within A549-
derived tumor xenografts. Already 2h after ITPP injection, a significant decrease in a hypoxia-detecting 
bioluminescent-based signal was measured, which indicates an increase in oxygen availability within 
the tumor tissue (Supplementary 1). This reporter protein consists of an oxygen dependent degradation 
domain fused to luciferase and is expressed in the respective cell line of interest.  
Different tumor entities vary in their susceptibility to develop hypoxia due to several factors: the genetic 
make-up and evolution of the tumor cell, and the size and location within the body. A high heterogeneity 
of the oxygen status also exists within the same tumor entities. In order to probe ITPP in an additional 
tumor entity, the oxygen-modulating capacities of ITPP were also assessed within tumor xenografts 
derived from the head and neck cancer cell line FaDu, in which hypoxia is less prevalent compared to 
A549-derived xenografts [47].  
In FaDu-derived xenografts, ITPP treatment lead to a significant increase in intratumoral oxygen 2h 
after the second ITPP treatment, which was applied on two consecutive days (Figure 9B). These results 
present ITPP as a competent oxygen-modulator for xenografts derived from two different cell lines. 
The characteristics of ITPP as a radiosensitizer were verified by an efficacy study in A549-derived 
xenografts (Figure 10B) and previously  in FaDu-derived xenografts (Figure 10A and [47]) as well. For 
radiotherapy in combination with ITPP, there is a significant survival prolongation in comparison to 
control irradiated mice caring xenografts. These results were expected because of the oxygen-enhancing 
effect: Through the increase in pO2, more ROS are generated, leading to an increased stabilization 
(“fixation”) of DNA DSBs in initially hypoxic zones of the tumors (or at least partially). This eventually 
translates into more effective tumor cell killing. 
This effect underlies the right shift of the oxygen-dissociation curve of hemoglobin upon ITPP 
treatment (Figure 6 and Figure 17) [53]. Because of an abnormal vasculature or an altered metabolism, 
cancer cells are not accurately delivered with oxygen. The right-shift within the oxygen-dissociation 
curve upon ITPP treatment resembles the facilitated liberation of oxygen from hemoglobin. Cancer 
cells with low oxygen content will receive more O2 and DNA damage can be fixed.  
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Since radiotherapy is one of the most relevant treatment modalities, alone or in combination with 
surgery, chemotherapy or molecularly targeted therapy, it is very important to invest in the modulation 
of oxygen within a tumor in order to increase treatment outcome and patient survival. Of interest is, 
that ITPP is currently being tested in a phase II clinical trial in combination with FOLFOX 
chemotherapy for non-resectable visceral tumors in the Department of Visceral Surgery at the 
University Hospital of Zurich [54].  
4.2 Hypoxic tumor cells experience more DNA DSBs upon irradiation in 
combination with ITPP 
Ionizing radiation primarily kills tumor cells by the induction of un- or falsely repaired DNA DSBs. 
Mechanistic investigations underlying the tumor growth delay, or the survival advantage respectively, 
upon irradiation in combination with ITPP were performed. While tumor control in response to 
extended irradiation protocols is due to full eradication of all proliferating cells (cell death or treatment-
induced senescence), tumor growth delay (as an endpoint in preclinical in vivo experiments with 
irradiation) is most probably due to only partial killing of the full number of cells present in a tumor 
xenograft and regaining of tumor proliferative activity of the surviving tumor cells.  
To get deeper insight of the underlying mechanism of the tumor growth delay, tumor xenografts derived 
from the FaDu cell line were irradiated and the amount of DNA DSBs were quantified using the DNA 
Figure 17 Shift of the oxygen-dissociation curve of hemoglobin to the right 
upon ITPP treatment, indicating the facilitated liberation of oxygen from 
hemoglobin. Figure adapted from [61]. 
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DSBs marker γH2AX. A short term (0.5h after irradiation) and a long term (24h after irradiation) 
timepoint were used to assess initial and residual DNA DSBs within hypoxic and normoxic regions. To 
stratify between zones with low pO2 (below 10 mmHg) and sufficient oxygen prior to treatment, 
marking of hypoxic zones by pimonidazole was used. For each tumor sample, three zones in hypoxic 
and three zones in normoxic areas of the tumor were chosen. For each zone, the γH2AX foci were 
counted in at least 100 cells. Mitotic, necrotic or cells with micronuclei were excluded from the analysis. 
In average, the same number of cells within a defined zone had to be excluded, proposing that this does 
not influence the result in average counted γH2AX foci per cell.  
Within normoxic zones, there is no difference in the number of γH2AX foci per cell for ITPP treatment 
alone. This indicates that ITPP does not have an additional effect regarding DNA DSBs induction in 
normoxic cells (Figure 13A).  
Hypoxic cells within unirradiated xenografts share a similar distribution of γH2AX foci per cell with 
normoxic cells and display no significant difference in average γH2AX foci per cell (Figure 13B). 
Regarding the number of foci within hypoxic cells shortly after irradiation (short term timepoint 0.5h 
after irradiation), there are significantly more γH2AX foci per cell in initially hypoxic cells which were 
ITPP treated right before irradiation (Figure 14A). This strongly supports the oxygen-enhancing effect, 
indicating that the amount of ROS and subsequent induction and fixation of DNA DSBs is lower in 
hypoxic cells without ITPP treatment. This is also clearly demonstrated in the number of cells with no 
γH2AX foci: Upon ITPP treatment, almost no pimonidazole-positive (i.e. hypoxic prior to ITPP-
treatment) cell remained undamaged regarding DNA DSBs (Figure 14A right), whereas for control 
irradiated pimonidazole-positive cells, almost 10% of cells did not respond, meaning they have no 
radiation-induced DNA DSBs. Cells which experience almost no irradiation-induced DNA DSBs are 
said to not respond to radiotherapy.  
For the long term timepoint after irradiation (24h), the average number of γH2AX foci per cell decreases 
for either treatment, indicating that DNA DSB repair was active.  
The remaining foci represent residual DNA damage that will eventually lead to eradication or 
senescence of the affected cells (Figure 14C and 14D). Again, significantly more DNA DSBs could be 
detected in ITPP treated, irradiated pimonidazole-positive tumor xenograft zones in comparison to PBS-
treated, irradiated pimonidazole-positive tumor xenograft zones (Figure 14C). As such, this quantitative 
difference in the amount of residual DNA DSB could translate into a more efficient treatment outcome. 
Of note is, that the residual γH2AX foci per cell is dependent on the initially induced DNA DSBs. 
The reason for the surprising difference in residual foci within normoxic cells for ITPP and control 
treated and irradiated cells (Figure 14D) could be that some zones were counted as normoxic when they 
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were actually slightly hypoxic but still less radiation-responsive. Pimonidazole staining is only accurate 
for a pO2 level below 10mmHg. In such case, pimonidazole-staining does not identify such slightly-
hypoxic cells. Furthermore, DNA-repair capacity could also be different in these intermediate zones 
(4.3). 
4.3 ITPP acts on the PI3K/AKT pathway 
The PI3K/AKT pathway is involved in a variety of cellular functions including growth, proliferation, 
metabolism, angiogenesis and survival. Hyperactivation of the PI3K/AKT pathway is linked to tumor 
development, progression and resistance to cancer therapies, such as radiotherapy. Furthermore, pAKT 
is involved in a correct DNA damage response (DDR). The in vitro ITPP treatment in combination with 
irradiation demonstrated an ITPP-dependent increase in PTEN levels, which is the main antagonist of 
this pathway. Concomitantly, a decrease in pAKT levels was observed.  
PI3K activity could be inhibited through binding of ITPP within its catalytic cleft, which is usually 
occupied by PIP2. The reduced phosphorylation of PIP2 leads to decreasing levels of PIP3. PIP3 is 
necessary to recruit AKT to the plasma membrane where its activation through phosphorylation will be 
mediated through other kinases. Through reduced levels of PIP3, pAKT levels decrease simultaneously 
– leading beside other effects –to a dysregulated DDR. Thus, the residual DNA damage could be due 
to reduced DNA DSB repair in irradiated and ITPP treated cells, and enhanced DNA DSB repair in 
control irradiated hypoxic cells (3.1.3). However, such quantitative correlations need to be 
demonstrated also as part of in vitro experiments, which were not performed in this thesis. Furthermore, 
the mechanism of ITPP-dependent increase of PTEN levels in different target cells was not investigated. 
Notably, it was not possible to demonstrate reduced clonogenic survival of FaDu cells pretreated with 
ITPP prior to irradiation. These results argue for a minor role of ITPP on the PI3K/AKT pathway in 
respect to act as a radiosensitizer in vitro.  
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5 Conclusion  
The aims of this Master’s Thesis included probing of the capacity of ITPP as a reoxygenator and 
radiosensitizer in tumor xenografts derived from different cancer cell lines (A549 and FaDu). Further, 
the mechanism underlying the tumor growth delay upon irradiation in combination with ITPP was 
investigated.  
It was demonstrated that ITPP leads to reoxygenation of hypoxic areas within tumors. These areas could 
then be linked to enhanced irradiation-induced initial and residual DNA DSBs in comparison to 
untreated and only irradiated hypoxic tumor areas. These increased levels of DNA DSBs are most 
probably responsible for the improved treatment response in tumor xenografts upon treatment with 
ITPP in combination with irradiation as compared to irradiation alone. Furthermore, it was also 
demonstrated that ITPP interferes with the PI3K/AKT signal transduction cascade. However, these 
intriguing results could not be further extended due to time reasons and must be examined in further 
detail in the future. Right now, several additional preclinical studies are ongoing in vivo in the 
Laboratory of Applied Radiobiology at the University Hospital of Zurich (USZ), to address the impact 
of ITPP in combination with irradiation in more advanced tumor models including orthotopic tumor 
models in immunocompetent mice.  
Overall, ITPP leads to a significantly better radiotherapy outcome in vivo. Therefore, it should be 
considered as a neoadjuvant treatment for radiotherapy. Importantly, as ITPP demonstrates its greatest 
power in reoxygenating hypoxic tissue, it should be administered to patients with a “hypoxia-driver 
phenotype”. In cancer treatment, the biggest chance for successful treatment lays in targeting the 
pathophysiological peculiarities of a certain cancer, and hypoxia is definitely one of those. Patients with 
the “hypoxia-driver phenotype” belong to a subgroup of cancer patients that will benefit most from the 
capabilities of ITPP to increase oxygen delivery into hypoxic tissue.  
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Supplementary 
All the preliminary data in this thesis and the rationale to combine ITPP with radiotherapy is based on 
the results of Ivo Grgic, PhD student at the USZ and tutor of this work. Prior to investigating the anti-
tumor effect of ITPP in combination with radiotherapy, an optimal dose regimen of ITPP and the ideal 
time-window for irradiation were defined in order to maximize the biological effect upon treatment. 
This was achieved by using the hypoxia-specific bioluminescent imaging approach described in this 
thesis (2.3.4) [49]. The reoxygenation capability of ITPP was assessed in xenografts derived from the 
non-small cell lung carcinoma (NSCLC) cell line A549 (Supplementary 1), since this cell line was 
already validated in view of hypoxia in several other projects within the Laboratory of Applied 
Radiobiology at the USZ. Dose escalation studies revealed a maximal tolerated dose of 3g/kg 
bodyweight ITPP, intraperitoneally injected on two consecutive days. The bioluminescence signal was 
always measured 2h after treatment injection in addition to a baseline signal.  
The reoxygenation of ITPP is already significant 2h after the first ITPP injection (Supplementary 1A). 
Supplementary 1 Representative images showing the effect of PBS and ITPP on tumor reoxygenation as 
determined by a A) hypoxia-specific and a B) hypoxia-unspecific bioluminescent in vivo imaging in A549-derived 
xenografts. Imaging was performed immediately before and 2h after PBS/ITPP (3mg/kg bodyweight) injection. 
There is a significant decrease in bioluminescent signal, indicating an increase in oxygen, 2h after ITPP treatment.  
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Previous in vivo efficacy-oriented tumor growth delay studies were carried out in xenografts derived 
from the head and neck squamous cell carcinoma (HNSCC) cell line FaDu (and not in A549-derived 
tumor xenografts as in investigated in this thesis), because of the interest claimed by NormOxys and 
the clinical relevance of HNSCC. Xenografts were treated on two consecutive days (ITPP/PBS) and 
after the second injection, tumor xenografts were irradiated with 10 Gy. Whereas ITPP treatment did 
not show any difference compared to control treatment (PBS), treatment with ITPP prior to irradiation 
significantly increased the tumor growth delay in comparison to irradiation alone (Figure 10A). 
In the scope of this work, complementary bioimaging and efficacy-oriented experiments were 
performed in FaDu-derived xenografts and A549-derived xenografts respectively. DNA-damage 
related endpoints were assessed in tumor xenografts derived from FaDu cells. Additionally, PI3K/AKT 
pathway-related experiments were performed in several cell lines in vitro. 
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